Navigation Links
Novel Facebook Application Aims to Prevent Cervical Cancer
Date:10/12/2009

Users can share interactive information on HPV anonymously

WASHINGTON, Oct. 12 /PRNewswire-USNewswire/ -- A new Facebook application has been launched to help educate, motivate and mobilize people to prevent the spread of Humanpapilloma Virus (HPV). "Fact Check: HPV" (www.hpvfactcheck.org) allows users to take an interactive, educational quiz about HPV, find additional resources, and commit to take action, while even allowing concerned friends to anonymously share the application with peers.

The application was developed by Partnership for Prevention and the University of Maryland's College of Information Studies with input from the School of Public Health. The project was funded by the Fund to Prevent Cervical Cancer.

"Use of social networking sites has skyrocketed in the last few years, becoming an excellent channel to promote healthy behaviors," said Robert J. Gould PhD, president of Partnership for Prevention. "Fact Check: HPV will harness the power of social media to increase awareness of this common sexually transmitted disease (STD)."

Use of social networking sites has quadrupled over the last four years from 8 percent in 2005 to over 35 percent in 2008. Over 75% of young adults, age 18-24, have a profile page, the vast majority of whom check it at least weekly.

"Young adults trust information recommended by friends, however, friends are often reticent to share information about stigmatized illnesses such as STDs, mental illnesses, or substance abuse. This project tests a novel strategy that spreads sensitive information through friendship networks, while still retaining anonymity." said Derek L. Hansen, PhD, Assistant Professor at University of Maryland's College of Information Studies. "It also helps us learn how the application spreads through the network and identify misperceptions about HPV based on quiz results."

A recent study conducted by the Centers for Disease Control and Prevention (CDC) found that one in four adolescent girls between the ages of 14-19, or 3.2 million teen girls, is infected with at least one of the most common sexually transmitted diseases -- (HPV, Chlamydia, Herpes, and Trichomoniasis). This study sheds new light on a chronic problem among adolescents in the United States -- one that often receives little attention, in part, due to the sensitive nature of the topic.

STDs can result in serious health consequences when left untreated, including cervical cancer and infertility, and cost the U.S. health care system millions of dollars in medical expenses.

Partnership for Prevention is a membership organization of business, nonprofit and government leaders working to make evidence-based disease prevention and health promotion a national priority. More information is available at www.prevent.org .

SOURCE Partnership for Prevention


'/>"/>
SOURCE Partnership for Prevention
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Toronto researchers discover novel circulation in human eye, new glaucoma treatment target
2. Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009
3. New Web Site Will Help Pennsylvanians Learn About, Protect Against Novel H1N1 Flu
4. The Uptake of Novel Therapies Will Drive the Obesity Drug Market to Increase More than Six-Fold to Over $3.2 Billion in 2018
5. Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
6. Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
7. Fifteenth US Patent Issued for aTyr Pharma Novel Biotherapeutic
8. Solution to PREVENT Novel H1N1 (Swine Flu) From Closing Down Schools!
9. The Cosmetic Bootcamp LLC Announces Novel Presentations at Its 3rd Annual Marketing and Management Symposium
10. Abbott to Collaborate With Pfizer Inc on Companion Diagnostic Test to Select Patient Candidates for Novel Investigational Non-Small Cell Lung Cancer Therapy
11. Carnegie Mellon Researchers Develop Novel Tool to Rank Death Rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... MELBOURNE, Australia (PRWEB) , ... February 23, 2017 , ... ... . With perseverance and disciplined exercise regime, the author was able to successfully recover. ... Vas-Don collates all relevant information for various sources on the principals of massage, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... in recent years. The technology is so cutting edge, in fact, the U.S. ... for stem cell procedures. However, successful patient outcomes in certain clinical stem cell ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... approach, leads to fewer trips the emergency room, fewer hospital admissions, and better ... Journal of Managed Care® (AJMC®) finds. The study can be found here ...
(Date:2/22/2017)... ... February 22, 2017 , ... Sideline Products participated in the World Horse Expo ... Tom Seay and his production crew. Tom Seay’s program “Best of America by ... Saddle Sidekicks will be featured on April 6, 2017. After the broadcast, the ...
(Date:2/22/2017)... ... 22, 2017 , ... The Centers for Medicare & Medicaid ... in Delaware, New Jersey, Pennsylvania and West Virginia prepare for and participate in ... Act of 2015 (MACRA). , This technical assistance, authorized and funded under ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... York , February 23, 2017 ... Holter Monitor Market are GE Healthcare, Koninklijke Philips N.V., ... about 48% in the global market in 2015. Strong ... two key factors assessed to be aiding these players ... Research states that the players in the global market ...
(Date:2/23/2017)... Mass. , Feb. 23, 2017   ... partner to global in vitro diagnostics manufacturers and ... series titled "Catalyzing Implementation of NGS-Based Tests" to ... March 30, 2017 at 11am Eastern Standard Time ... is to highlight the need for improved performance ...
(Date:2/23/2017)... , Feb. 23, 2017 MabVax ... oncology drug development company, announces that it has ... Administration (FDA) authorizing the initiation a Phase I ... for pancreatic cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is ... MabVax plans to initiate the phase I clinical ...
Breaking Medicine Technology: